Bioasis Technologies Inc. Confirms TSXV Approval of Warrant Extension and Repricing
March 24 2021 - 5:15PM
BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF;),
(“
Bioasis” or the “
Company”), a
pre-clinical, research-stage biopharmaceutical company developing
its proprietary xB3 ™ platform technology for the delivery of
therapeutics across the blood-brain barrier (BBB) and the treatment
of CNS disorders in areas of high unmet medical need, including
brain cancers and neurodegenerative diseases, is pleased to confirm
that it has received approval from the TSX Venture Exchange for the
previously announced amendments to the terms of 5,797,795 common
share purchase warrants issued to subscribers pursuant to the
private placement of units which closed on April 11, 2017. The
expiry date of the warrants has been extended from April 11, 2021
until April 11, 2022 and exercise price has been reduced from $1.00
to $0.85.
All other terms of the warrants remain unchanged for the
extended exercise period.
Contacts
On behalf of the Board of Directors of Bioasis Technologies
Inc.
Deborah RathjenExecutive Chair of the Boarddeborah@bioasis.us+1
203 533 7082
Follow on
FacebookInstagramLinkedInTwitter
BTI-CRP
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company
developing the xB3 ™ platform, a proprietary technology for the
delivery of therapeutics across the blood brain barrier and the
treatment of CNS disorders in areas of high unmet medical need,
including brain cancers and neurodegenerative diseases. The
delivery of therapeutics across the blood brain barrier represents
the final frontier in treating neurological disorders. The in-house
development programs at Bioasis are designed to develop symptomatic
and disease-modifying treatments for brain-related diseases and
disorders. For more information about the Company, please visit
www.bioasis.us.
Forward Looking StatementsCertain statements in
this press release contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities
legislation that may not be based on historical fact along with
other statements containing the words “believe,” “may,” “plan,”
“will,” “estimate,” “continue,” “anticipate,” “intend,” “expect”
and similar expressions. Such forward-looking statements or
information involve known and unknown risks, uncertainties and
other factors that may cause our actual results, events or
developments, or industry results, to be materially different from
any future results, events or developments express or implied by
such forward-looking statements or information. Such factors
include, among others, our stage of development, lack of any
product revenues, additional capital requirements, risk associated
with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our
intellectual property, dependence on collaborative partners and the
prospects for negotiating additional corporate collaborations or
licensing arrangements and their timing. Specifically, certain
risks and uncertainties that could cause such actual events or
results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results
expressed or implied by such statements and information include,
but are not limited to, the risks and uncertainties that: products
that we develop may not succeed in preclinical or clinical trials,
or future products in our targeted corporate objectives; our future
operating results are uncertain and likely to fluctuate; we may not
be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the
costs of launching our products may be greater than anticipated; we
have no experience in commercial manufacturing; we may face unknown
risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and
other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Apr 2023 to Apr 2024